|
背景介绍: PI3K/AKT/mTOR是调控细胞生长、增殖、代谢与存活的核心通路,在肿瘤、免疫及遗传疾病中常异常激活。Ⅰ类PI3K由催化亚基p110与调节亚基p85/p84组成,受RTK、GPCR及RAS激活,将PI(4,5)P₂转化为第二信使PI(3,4,5)P₃,进而招募并激活AKT;AKT通过抑制TSC1/2激活mTORC1,调控蛋白合成与细胞生长。PTEN为主要负调控因子,可逆转上述反应。该通路异常多源于PIK3CA激活突变、AKT1突变或PTEN缺失,是癌症与靶向耐药的关键驱动因素,因其高度可药性,已成为药物研发的重要靶点。[1,2]
图1. Ⅰ类PI3K信号通路[1]
参考文献: [1] Conduit Sarah E., et al. A Renaissance in Targeting the PI3K/AKT/mTOR Pathway. Nature Reviews Drug Discovery, 30 Mar. 2026. [2] He Yan, et al. Targeting PI3K/Akt Signal Transduction for Cancer Therapy. Signal Transduction and Targeted Therapy, vol. 6, no. 1, 16 Dec. 2021, p. 425. |
相关产品
- Inavolisib
- Paxalisib (GDC-0084)
- Copanlisib (BAY 80-6946)
- Duvelisib (IPI-145)
- Everolimus (RAD001)
- Eganelisib (IPI-549)
- Sapanisertib (MLN0128)
- Gedatolisib (PKI-587)
- Miransertib (ARQ092)
- Bimiralisib (PQR309)
- Afuresertib (GSK2110183)
- Capivasertib (AZD5363)
- Temsirolimus
- Rapamycin (Sirolimus)
- Idelalisib (CAL-101, GS-1101)
- Alpelisib (BYL719)


鲁公网安备37011202002432号